Early TIPS (n = 29) compared to large-volume paracenteses and albumin infusion (LVP+A) (n = 33).
Early TIPS (n = 66) compared to pharmacotherapy+endoscopic band ligation (EBL) (n = 605). Child-Pugh C patients with scores < 14.
†
*
Controlled expansion sleeve
Radiopaque gold
markers
Unlined portal region
Nitinol frame
expanded polytetrafluoroethylene (ePTFE) graft-lining
GORE
®
VIATORR
®
TIPS
Endoprosthesis
with Controlled Expansion
Compelling evidence points to earlier transjugular intrahepatic portosystemic shunt (TIPS) creation to help physicians increase survival in high-risk liver disease patients.
TIME TO RETHINK TIPS
GORE
®
VIATORR TIPS
®
Endoprosthesis with
Controlled Expansion
Reduce portal pressure with diameter control, see illustration for list of features:
Click to explore
Learn more
goremedical.com
References
W. L. Gore & Associates, Inc.
Asia Pacific
+65 67332882
Australia/New Zealand
1800 680 424
Europe
00800 6334 4673
United States
Flagstaff, AZ 86004 800 437 8181 928 779 2771
INDICATIONS FOR USE IN THE U.S.: The GORE VIATORR TIPS Endoprosthesis is indicated for use in the de novo and revision treatment of portal hypertension and its complications such as variceal bleeding, gastropathy, refractory ascites and/or hepatic hydrothorax.
®
®
Refer to at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available.
Products listed may not be available in all markets.
GORE, VIATORR and designs are trademarks of W. L. Gore and Associates.
© 2022 W. L. Gore & Associates, Inc. 22495102-EN MARCH 2022
goremedical.com/rethinkTIPS
Find videos, patient resources and more at:
Devices implanted
150K+
Publications
500+
Years of performance
20+
* Early TIPS (n = 29) compared to large-volume paracenteses and albumin infusion (LVP+A) (n = 33).
Early TIPS (n = 66) compared to pharmacotherapy+endoscopic band ligation (EBL) (n = 605). Child-Pugh C patients with scores < 14.
†
Data shows earlier TIPS increases survival and reduces complications, helping improve the quality of life for select liver disease patients.
Consider the data
When is earlier?
At least two large-volume paracenteses (LVP) within
three weeks
Ascites¹
TIPS within
of admission after bleeding incident
hours
Variceal bleeding²
Instructions for Use
Together, improving life,
Higher transplant-free survival at one year*
Survival¹
Clinical outcomes¹
Recurrence¹
Footnote +
Hepatic encephalopathy (HE)¹
probability of remaining
free of HE
TIPS
LVP+A ( = .868)
=
%
%
vs.
Number of paracenteses required to treat ascites following
placement of Endoprosthesis compared to paracentesis treatment alone.
®
VIATORR
GORE
®
Less recurrence of ascites
No difference in HE
total number of paracenteses
(TIPS n = , LVP+A n = )
TIPS
LVP+A ( < .001)
vs.
See additional data
large-volume paracenteses and albumin infusion (LVP+A)
( = .003)
P
%
%
TIPS
vs.
Less frequent de novo ascites or worsening of previous ascites
in Child-Pugh B with active bleeding (AB) and C patients
Higher survival
in Child-Pugh C patients with acute variceal bleeding (AVB) at one year
†
Footnote +
experienced HE
vs.
vs.
vs.
Greater freedom from rebleeding and treatment failure
No significant difference in HE
freedom from failure to control bleeding or prevent rebleeding in Child-Pugh B+AB and C patients
pharmacotherapy+EBL
P
( < .001)
.%
TIPS
.%
vs.
TIPS
%
( = .017)
P
pharmacotherapy+EBL
%
Ascites
Variceal bleeding
TIPS
%
pharmacotherapy+endoscopic band ligation (EBL)
( = .002)
P
%
pharmacotherapy+EBL
( = .863)
P
.%
TIPS
.%
Consider the evidence for earlier TIPS
Variceal bleeding²
Survival²
Clinical outcomes²
Recurrence²
Hepatic encephalopathy (HE)²
*
†
Early TIPS (n = 29) compared to large-volume paracenteses and albumin infusion (LVP+A) (n = 33).
Early TIPS (n = 66) compared to pharmacotherapy+endoscopic band ligation (EBL) (n = 605). Child-Pugh C patients with scores < 14.
See additional data
Radiopaque gold
markers
P
P
Footnote +
Download the data
*
†
Early TIPS (n = 29) compared to large-volume paracenteses and albumin infusion (LVP+A) (n = 33).
Early TIPS (n = 66) compared to pharmacotherapy+ endoscopic band ligation (EBL) (n = 605). Child-Pugh C patients with scores < 14.
Variceal bleeding²
Ascites¹
Variceal bleeding²
Ascites¹
TIPS
VIATORR
Number of paracenteses required to treat ascites following
placement of Endoprosthesis compared to paracentesis treatment alone.
Endoprosthesis compared to
Bureau C, Thabut D, Oberti F, et al. Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites. Gastroenterology 2017;152(1):157–163.
Hernández-Gea V, Procopet B, Giráldez Á, et al; International Variceal Bleeding Observational Study Group and Baveno Cooperation. Preemptive-TIPS improves
outcome in high-risk variceal bleeding: an observational study. Hepatology 2019;69(1):282-293. https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/hep.30182
1.
2.
1.
2.
Bureau C, Thabut D, Oberti F, et al. Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites. Gastroenterology 2017;152(1):157–163.
Hernández-Gea V, Procopet B, Giráldez Á, et al; International Variceal Bleeding Observational Study Group and Baveno Cooperation. Preemptive-TIPS improves outcome in high-risk variceal bleeding: an observational study. Hepatology 2019;69(1):282-293. https://aasldpubs.onlinelibrary.wiley.com/doi/full/
10.1002/hep.30182
INDICATIONS FOR USE UNDER CE MARK: The GORE VIATORR TIPS Endoprosthesis is indicated for use in the treatment of portal hypertension and its complications such as: variceal bleeding refractory to, or intolerant of, conventional therapies, inaccessible varices, gastropathy, refractory ascites and/or hepatic hydrothorax.
®
®
INDICATIONS FOR USE IN THE U.S.: The GORE VIATORR TIPS Endoprosthesis is indicated for use in the de novo and revision treatment of portal hypertension and its complications such as variceal bleeding, gastropathy, refractory ascites and/or hepatic hydrothorax.
®
®